As Chief Medical Officer, Judy is responsible for all clinical and medical activities in the company, moving Arthex’s compounds into clinical studies and through clinical development. Judy started her career as a clinical neurologist and clinical trial investigator in Canada. In the late 1990s, Judy joined Quintiles (now IQVIA) in the US as Medical Director and head of a project management group working in the neurology space. She then took on leadership roles at Serono (Now Merck KgA) in Geneva, Switzerland, Teva Neuroscience (Kansas City, MO) and then returned to Quintiles/IQVIA in 2008 as VP Strategic Drug Development group. In April 2017, Judy was appointed Chief Medical Officer at Cerecin, a US- Singapore biotech company developing drugs for neurological disorders. In 2021, Judy joined Arthex Biotech as CMO. In her current role, along with other members of Arthex Biotech’s Management Team, Judy has been instrumental in securing funding for Arthex’s next phase of growth, building a global regulatory and clinical drug development team, and establishing a clinical and a regulatory strategy for Arthex’s lead investigational drug, ATX-01 in Myotonic Dystrophy, as well as guiding the development of new assets in the pipeline. Judy’s extensive experience and passion in neurological drug development are critical to shepherd ATX-01 and Arthex’s newer projects towards the ultimate goal of developing drugs for patients that will make a difference to their lives.
